Expert Interview
Discussing Antares's and Lipocine's TLANDO for testosterone replacement therapy, following its receipt of US FDA approval March 29, 2022
Ticker(s): ATRS, LPCN, HALOInstitution: Weill Cornell Medicine
- Professor of Urology at Cornell Medicine, Past President of the Board of the American Society of Reproductive Medicine, and President of the Society for Male Reproduction/Urology
- Treats 300 patients annually with Hypogonadism and has treated over 4000 mean with severe male infertility.
- Developed novel hormonal therapies for men with impaired testosterone production and is an internationally acclaimed expert in the treatment of male infertility with over 300 published or submitted original manuscripts
Please describe your clinical practice. How many patients with hypogonadism do you see on a yearly basis?
Added By: slingshot_insightsWhat are the most common causes of hypogonadism in your patients? Is treatment differentiated depending on the underlying cause(autoimmune. genetic disorders. severe infections, etc)?
How often do you prescribe Hormone Replacement Therapy (HRT) to your patients, and what is your most commonly prescribed HRT?
What is lacking in the HRT space? What would you like to see in new therapies?
Has dosing regimen been an issue for your patients before? How does Tlando’s once-daily dosing compare?
Can you please discuss the recently released Peer-Reviewed Publication of the Phase 3 Study for TLANDO? Post-treatment with 450 mg testosterone undecanoate daily dose without dose adjustment, 80% of subjects (95% confidence interval of 72%–88%) achieved a testosterone Cavg in the normal range and restored testosterone levels to mean testosterone Cavg of 476 ± 184 ng/dl at steady state. How does it compare to other approved testosterone replacement therapy products?
How likely would you be to switch patients to Tlando?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
